Number 5: Biosimilar insulin glargine struggles for market share in the UK, facing pricing challenges and prescriber inertia ...

Discover the latest advancements in biosimilars, including tocilizumab's new indication, and partnerships for omalizumab and ...

Researchers analyze the quality of monoclonal antibody biosimilars in Japan, revealing variations that impact adoption and ...

CT-P47 emerges as a promising tocilizumab biosimilar, demonstrating comparable efficacy and safety in rheumatoid arthritis ...

The dulaglutide biosimilar LY05008 demonstrated equivalent efficacy in reducing HbA1c, along with comparable safety and ...

CT-P6 demonstrates strong efficacy and safety in HER2-positive advanced gastric cancer, achieving an 82% disease control rate in real-world settings.

Peter Pitts is president and co-founder of the Center for Medicine in the Public Interest. He also serves as a visiting professor at the University of Paris School of Medicine. Pitts is a former ...

Tyler Sandahl, PharmD, a clinical pharmacist at Mayo Clinic, supports biosimilars for cost savings but foresees challenges adopting an intravenous daratumumab biosimilar, preferring the more ...

Chad Pettit, MBA, is the executive director of global value access and policy for Amgen’s Biosimilars Business Unit. He develops global market access launch strategy for Amgen’s portfolio of 10 ...

Number 5: Global regulatory advancements in biosimilars enhance access to affordable treatments for autoimmune disorders, ...

In the second setback this year for etanercept biosimilars, the US District Court for the District of New Jersey has ordered Samsung Bioepis to delay marketing Eticovo until 2029.